Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation ...
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin ...